Clinical Trial Update: A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease [Phase 3]

View source ↗

Summary

A Roche-sponsored Phase 3 trial update announcing induction therapy with Afimkibart (RO7790121) for moderately to severely active Crohn's disease, currently rec…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Crohn Disease

Drugs mentioned

• Afimkibart (RO7790121)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Moderately to Severely Active Crohns Disease | Phase 3 | Status: RECRUITING